170928 presentation bioconnection (smb meeting)
TRANSCRIPT
![Page 1: 170928 Presentation BioConnection (SMB meeting)](https://reader031.vdocument.in/reader031/viewer/2022030317/5a651b8d7f8b9aa2548b725d/html5/thumbnails/1.jpg)
C M C
Alexander WillemseCEO BioConnection
Chief Executive Optimist
![Page 2: 170928 Presentation BioConnection (SMB meeting)](https://reader031.vdocument.in/reader031/viewer/2022030317/5a651b8d7f8b9aa2548b725d/html5/thumbnails/2.jpg)
E s t a b l i s h e d i n 2 005
Funded by Dutch governmentali n i t i a t i v e s ( 1 0 0 % )
YTD: solid customer base +proven business concept
Several ‘best-in-class’ EUmanufacturing partners
Located at the Life SciencesPark in Oss (Pivot park)
![Page 3: 170928 Presentation BioConnection (SMB meeting)](https://reader031.vdocument.in/reader031/viewer/2022030317/5a651b8d7f8b9aa2548b725d/html5/thumbnails/3.jpg)
BRIDGING THE CMC GAP
Active Pharmaceutical Ingredient
Registration
Clinical Trials
Market
Discovery
Development (formulation, lyo cycle,
analytics) &validation
Clinical scale F&F + freeze drying
Stability studies Label &
pack
Commercial scale F&F + freeze
drying
![Page 4: 170928 Presentation BioConnection (SMB meeting)](https://reader031.vdocument.in/reader031/viewer/2022030317/5a651b8d7f8b9aa2548b725d/html5/thumbnails/4.jpg)
OUR BUILDING BLOCKS
CLIENT
![Page 5: 170928 Presentation BioConnection (SMB meeting)](https://reader031.vdocument.in/reader031/viewer/2022030317/5a651b8d7f8b9aa2548b725d/html5/thumbnails/5.jpg)
SYNTHESIS & DEVELOPMENT OF COMPLEXP A R T I C L E S
L I P O S O M E S
NANO-SUSPENSIONS
M I C R O S P H E R E S
LEADER IN CHALLENGING
![Page 6: 170928 Presentation BioConnection (SMB meeting)](https://reader031.vdocument.in/reader031/viewer/2022030317/5a651b8d7f8b9aa2548b725d/html5/thumbnails/6.jpg)
![Page 7: 170928 Presentation BioConnection (SMB meeting)](https://reader031.vdocument.in/reader031/viewer/2022030317/5a651b8d7f8b9aa2548b725d/html5/thumbnails/7.jpg)
![Page 8: 170928 Presentation BioConnection (SMB meeting)](https://reader031.vdocument.in/reader031/viewer/2022030317/5a651b8d7f8b9aa2548b725d/html5/thumbnails/8.jpg)
![Page 9: 170928 Presentation BioConnection (SMB meeting)](https://reader031.vdocument.in/reader031/viewer/2022030317/5a651b8d7f8b9aa2548b725d/html5/thumbnails/9.jpg)
6 40
12
4
SERVING CLIENTS WORLDWIDESince 2005
1
![Page 10: 170928 Presentation BioConnection (SMB meeting)](https://reader031.vdocument.in/reader031/viewer/2022030317/5a651b8d7f8b9aa2548b725d/html5/thumbnails/10.jpg)
PROJECT DISTRIBUTION
Production &Development
Full service
Production
38%
33%
12%
17%
Markets
EU NL US ROW
(complex)small molecule
49%
Vaccine4%
Protein30%
Fusion protein2%
MAb4% Peptide
11%
API type
![Page 11: 170928 Presentation BioConnection (SMB meeting)](https://reader031.vdocument.in/reader031/viewer/2022030317/5a651b8d7f8b9aa2548b725d/html5/thumbnails/11.jpg)
CAPABILITIES
Batch size liquid product: • 2 – 50 L (200L in flexbags)
Freeze-Drier:• Shelf surface 1 x 3 m2
Fill volumes vials:• 0.5 ml – 50 ml
Fill volumes syringes:• 0.5 ml – 10 ml• Luer lock, stack-needles etc• Batch size: 5,000 syringes
per hour
FDA and EMA approvedTerminal sterilizationManual fill
Availablesizes
Liquid product
in vials
Lyophilized
product
2 R DIN 12,500 11,000
6 R DIN 10,000 5,700
10 R DIN 10,000 4,800
20 R DIN 6,000 3,000
25 R DIN 6,000 3,000
50 ml 6,000 1,400
![Page 12: 170928 Presentation BioConnection (SMB meeting)](https://reader031.vdocument.in/reader031/viewer/2022030317/5a651b8d7f8b9aa2548b725d/html5/thumbnails/12.jpg)
![Page 13: 170928 Presentation BioConnection (SMB meeting)](https://reader031.vdocument.in/reader031/viewer/2022030317/5a651b8d7f8b9aa2548b725d/html5/thumbnails/13.jpg)
BIOCONNECTION NEW CAPABILITIES
D-class process development room with state-of-the-art TFF equipment
Opened in 2017, suited for development and GMP
![Page 14: 170928 Presentation BioConnection (SMB meeting)](https://reader031.vdocument.in/reader031/viewer/2022030317/5a651b8d7f8b9aa2548b725d/html5/thumbnails/14.jpg)
BIOCONNECTION NEW CAPABILITIES
C-class flexible GMP setup (fifth floor, open to changes)
- Small scale areas- In-room A class isolator- Handfill with freeze-dry capacity- BSL-2 license for cell therapy- Supported by trained operators- Available for rental- Estimated opening: Q1-2018 -> Development under D, GMP in C
Second filling line with enhanced capacity
- Tunnel approach instead of sequential manual process steps- Estimated opening: 2019/2020
![Page 15: 170928 Presentation BioConnection (SMB meeting)](https://reader031.vdocument.in/reader031/viewer/2022030317/5a651b8d7f8b9aa2548b725d/html5/thumbnails/15.jpg)
![Page 16: 170928 Presentation BioConnection (SMB meeting)](https://reader031.vdocument.in/reader031/viewer/2022030317/5a651b8d7f8b9aa2548b725d/html5/thumbnails/16.jpg)
CONTACT
Joost CornelissenBusiness Development ManagerE: [email protected]
Dennis LinkBusiness Development ManagerE: [email protected]
Sjaak StevenseDirector Marketing & SalesE: [email protected]
K l o o s t e r s t r a a t 95 3 4 9 A B O s sThe Nether lands
www.bioconnection.eu
B I O C O N N E C T I O N